Shares of 10x Genomics, Inc. (TXG) surged 8.77% in after-hours trading on Thursday, following the release of the company's impressive third-quarter 2025 financial results that exceeded analyst expectations. The biotech firm, known for its innovative genomics and single-cell analysis technologies, reported better-than-anticipated earnings and revenue figures, sparking investor enthusiasm.

For the third quarter, 10x Genomics posted earnings per share (EPS) of $(0.22), beating the estimated $(0.29). Revenue came in at $149.002 million, surpassing the forecast of $142.490 million. The company's gross margin stood at a healthy 67%, indicating strong profitability in its core operations. Despite reporting a net loss of $27.5 million for the quarter, the narrower-than-expected loss bolstered investor confidence.

Adding to the positive sentiment, 10x Genomics provided an optimistic outlook for the fourth quarter, projecting revenue between $154 million and $158 million. This forward-looking guidance suggests continued growth and appears to have contributed significantly to the stock's after-hours rally. Investors seem to be betting on the company's potential for future expansion in the rapidly evolving genomics market, as reflected in the substantial stock price increase following the earnings release.